Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
Clinique Claude Bernard, Albi, France
Institut Bergonie, Bordeaux, France
Centre Paul Papin, Angers, France
Cancer Therapy and Research Center, San Antonio, Texas, United States
National Naval Medical Center, Bethesda, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.